



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 27-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 01-11-2008 TO BE PUBLISHED 18-11-2008 IN THE GAZETTE OF PAKISTAN PART-V.

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 27-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 01-11-2008 TO BE PUBLISHED 18-11-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1273/2008	<u>27-10-2008</u> Bayer Technology Services GmbH, Germany (Priority 30-10-07 Germany)	“Process for heterogeneously catalysed esterification of fatty acids”
1274/2008	Schering Corporation, USA (Priority 29-10-07 USA)	“Thiazole derivatives and methods of use thereof”
1275/2008	Janssen Pharmaceutica N.V., Belgium (Priority 31-10-07 USA)	“Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase”
1276/2008	Eli Lilly and Company, USA (Priority 02-11-07 USA)	“Anti-hepcidin antibodies and uses thereof”
1277/2008	1. Innogenetics NV. Belgium 2. Inserm France 3. Sanofi-Aventis France (Priority 29-10-07 Europe)	“New antibodies specific of the β -amyloid peptides and their uses as diagnostic agents or drugs”
1278/2008	<u>28-10-2008</u> Muhammad Yasin Khan PCSIR, Karachi	“Solar food dryer”
1279/2008	Lubrication Systems Company of Texas, LLC, USA, (Priority 21-4-08 USA)	“Self Aligning Bearing and Seal Assembly”
1280/2008	H. Lundbeck A/S, Denmark, (Priority 29-10-07 Denmark)	“Modified absorption formulation of gaboxadol”
1281/2008	MCP Operations Pty Ltd, Australia, (Priority 1-11-07 Australia)	“Improved Tablet Coating”

1282/2008	Takeda Pharmaceutical Company Limited, Japan, (Priority 29-10-07 Japan)	“Drug for prophylaxis or treatment of cancer”
1283/2008	Syngenta Participations AG, Switzerland, (Priority 6-11-07 GB)	“ Chemical Compounds”
1284/2008	Syngenta Participations AG, Switzerland, (Priority 7-11-07 GB)	“ Chemical Compounds”
1285/2008	Celanese International Corporation, USA, (Priority 30-10-2007 USA)	“ Acetaldehyde removal from methyl acetate by distillation at elevated pressure”
1286/2008	Cooltech Applications, France, (Priority 30-10-07 France)	“Heat Generator with magnetocaloric material”
1287/2008	1. China Mobile Communication Corp. Design Institute Ltd. 2. China Mobile Communication Corporation 3. China Mobile Communication Corp. Fujian. Ltd China (Priority 29-10-07 China)	“Method and apparatus of using drive test data for propagation model calibration”
1288/2008	<u>29-10-2008</u> Bayer Schering Pharma Aktiengesellschaft Germany (Priority 05-11-07 Europe)	“Use of a gestagen in combination with an oestrogen and one or more pharmaceutically acceptable excipients/carriers, for lactose-free oral contraception”
1289/2008	CORMAN S.A., Belgium (priority 29-10-07 Europe)	“Method for reducing the saturated fatty acid content of milk fat, products obtained and applications thereof”

1290/2008	Merck & Co., Inc. USA Divisional	“A composition comprising residronate”
1291/2008	Merck & Co., Inc. USA Divisional	“A composition comprising residronate”
1292/2008	Schering Corporation USA (priority 31-10-07 USA)	“Macrocyclic inhibitors of hepatitis C virus NS3 serine protease”
	<u>30-10-2008</u>	
1293/2008	Ten Cate Advanced Textiles B.V., Netherlands (priority 31-10-07 Europe)	“Reciprocating Print Head Arrangement and Method of Depositing a Medium”
1294/2008	Wyeth, USA, (Priority 1-11-2007 USA)	“ Antibodies to GDF8 as uses thereof”
1295/2008	H. Lundbeck A/S, Denmark, (Priority 12-3-04 Denmark) Divisional	“ Substituted morpholine and thiomorpholine derivatives”
1296/2008	AstraZeneca AB, Sweden, (Priority 24-12-02 Europe) Divisional	“ Process for the preparation of the quinozoline compound”
1297/2008	Saeed Ahmad Awan, Lahore, Pakistan.	“Ergonomic loom for weaving hand made carpets”
	<u>31-10-2008</u>	
1298/2008	Abbott GmbH & Co KG, Germany, (Priority 20-11-07 EP)	“ 1,2,4- triazin – 3, 5- dione compounds suitable for treating disorders that respond to modulation of the dopamine D ₃ Receptor”
1299/2008	Otsuka Pharmaceutical Co, Ltd, Japan, (Priority 31-10-07 USA)	“ Uses of a glycoprotein VI (GPVI) Inhibitor”

1300/2008	Abbott GmbH & Co KG, Germany, (Priority 02-11-07 USA)	“ Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT ₆ receptor”
1301/2008	Vestergaard Frandsen SA, Switzerland, (Priority 5-11-07 PCT)	“ Room with two counter – resistant insecticidal objects”
1302/2008	LG Life Sciences Ltd, Korea, (Priority 8-11-07 Korea)	“ Syringe system and drug container”
1303/2008	Novartis AG, Switzerland, (Priority 2-11-07 USA)	“ Molecules and methods for modulating complement component”
	<u>01-11-2008</u>	
1304/2008	1. Azra Khanum, 2. Sumbul Khalid, 3. Sardar Faisal Mahmood, 4. Qudsia Bashir, 5. Muhammad Jadoon Khan, 6. Hamamah Islam Butt, 7. Mirza Imran Shahzad and 8. Muhammad Arif Nadeem Arid Agriculture University, Rawalpindi, Pakistan	“Plasmid based therapeutic agents: indigenous buffalo and caprine somatotropins”

☒☒☒☒☒☒☒

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

778/1996	F. Hoffmann-La Roche AG., Switzerland	“Novel hydroxamic acid compound” CO7D 295/04
----------	---	---

139840

Compound of the formula:



wherein:

n is 0, 1 or 2;

Y is hydroxy or XONH-, where X is hydrogen or lower alkyl;

R¹ is hydrogen or lower alkyl;

R² is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl,

arylheteroalkyl, cycloalkyl, cycloalkylalkyl,

heteroaryl, heteroaralkyl, heteroarylheteroalkyl,

heterocyclo, heterocyclo-lower alkyl, heterocyclo-lower heteroalkyl or -NR⁶R⁷, wherein:

R^6 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R^7 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, $-COR^8$, $-CONR^8R^9$, $-SO_2NR^8R^9$, $-SO_2R^{10}$, aryloxycarbonyl, or alkoxycarbonyl; or R^6 and R^7 together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein R^8 and R^9 are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R^{10} is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R^1 and R^2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R^3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R^4 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R^2 and R^3 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R^3 and R^4 together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R^5 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.

147/2001 Wyeth, USA.

“Nutritional composition containing oligofructose and sialyllactose”

(A61K, 31/70)

139841

A nutritional composition is provided which comprises oligofructose and sialyllactose. The composition promotes growth of beneficial microorganisms and inhibits pathogenic organisms.

131/2002


Syngenta
Participations AG.,
Switzerland

“A compound of avermectin substituted in the 4th-
position”

139842

(A01N, 43/90, C07H, 19/01)

A compound of formula



wherein

Xⁿ⁻ is an anion;

n is 1, 2, 3 or 4;

R₁ is C₁-C₁₂alkyl, C₃-C₈cycloalkyl; or C₂-C₁₂alkenyl;

R₂ is hydrogen, unsubstituted or substituted C₁-C₁₂alkyl or C₂-C₁₂alkenyl;

R₃ is hydrogen, unsubstituted or substituted C₁-C₁₂alkyl, C₃-C₁₂cycloalkyl, C₂-C₁₂alkenyl; or C₁-C₁₂alkynyl; or .

R₂ and R₃ together are an alkylene or alkenylene bridge;

and, where applicable, E/Z isomers, E/Z isomeric mixture and/or tautomer;

with the proviso that R₁ is not sec-butyl or isopropyl when R₂ is H and R₃ is methyl;

and, where applicable, their possible tautomer; a process for the preparation of those compounds and its tautomer and the use thereof; pesticidal composition in which the active ingredient has been selected from those compound and its tautomer; and a process for the preparation of composition and the use thereof and, where applicable, its tautomer, in free form or are described.


990/2002 Novartis AG.,
Switzerland

“Heterocyclic compound containing substituted
benzenesulfonyl-azetidine-2-carboxylic acid”

(CO7D, 207/48)

139843

Compound of the formula



provide pharmacological agent which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compound of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compound of the present invention is particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred is the compound of the invention which are dual agonists of PPAR α and PPAR γ receptors.


225/2005 LES Laboratoires
Servier,
France

“New B crystalline form of perindopril tert-
butylamine and a process for its preparation”

(CO7D, 209/42, A61K 31/404)

139844

B crystalline form of the compound of formula (I)




Characterised by its power X-ray diffraction diagram.

984/2006 F. Hoffmann-LA
Roche AG.,
Switzerland

“Ester of novel hydroxamic acid derivative”
(CO7D, 295/04)

139845

An ester of compound of the formula:



wherein:

n is 0, 1 or 2;

Y is hydroxy or XONH-, where X is hydrogen or lower alkyl;

R¹ is hydrogen or lower alkyl;

R² is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl,

arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocyclo-lower alkyl, heterocyclo-lower heteroalkyl or -NR⁶R⁷, wherein:

R⁶ is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and

heteroaralkyl; R⁷ is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, -COR⁸, -CONR⁸R⁹, -S₂NR⁸R⁹,

-SO₂R¹⁰, aryloxycarbonyl, or alkoxy carbonyl; or R⁶ and R⁷ together with the nitrogen atom to which they are attached represent a heterocyclo

group; wherein
 R^8 and R^9 are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R^{10} is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R^1 and R^2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R^3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R^4 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R^2 and R^3 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R^3 and R^4 together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R^5 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroarylly or heteroaralkyl; or pharmaceutically acceptable salt exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.


985/2006 F. Hoffmann-LA
 Roche AG.,
 Switzerland

“Salt of novel hydroxamic acid derivative”

(CO7D, 295/04)

139846

Pharmaceutical salt of compound of the formula:



wherein:

n is 0, 1 or 2;

Y is hydroxy or $XONH-$, where X is hydrogen or lower alkyl; R^1 is hydrogen or lower alkyl;

R^2 is hydrogen, lower alkyl, heteroalkyl, aryl,

aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocyclo-lower alkyl, heterocyclo-lower heteroalkyl or $-NR^6R^7$, wherein:

R^6 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R^7 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, $-COR^8$, $-CONR^8R^9$; $-SO_2NR^8R^9$, $-SO_2R^{10}$, aryloxy carbonyl, or alkoxy carbonyl; or R^6 and R^7 together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein

R^8 and R^9 are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R^{10} is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R^1 and R^2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R^3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl,

aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy;

R^4 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R^2 and R^4 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R^3 and R^4 together with the carbon to which they are attached

represent a cycloalkyl or heterocyclo group; and R^5 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or pharmaceutically acceptable salt or ester thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.

475/2007 Bristol Myers
Squibb Company,
USA.

“Diketo-piperazine compound as antiviral agent”
(CO7D, 403/12, A61K 31/437)

This disclosure provides compound having drug and bio-affecting properties, its pharmaceutical composition and method of use. In particular, the disclosure is concerned with diketo piperazine derivative that possess unique antiviral activity. More particularly, the present disclosure relates to compound useful for the treatment of HIV and AIDS.

1040/2007 Y.K.K. saglik Hizmetleri Limited Sirketi, Turkey

“Flexible and rigid resector balloon”

(A61B, 17/22, A61M, 25/10)

139848

The present invention relates to resector balloons (1) employed in treating endoluminal-endiobronchial tumoral lesions and endovascular occlusions encountered in blood vessels and in other hollow tube-like organs (7) such as trachea-bronchial, windpipe food pipe, urinary tract, bile ducts. Said resector balloon (1) is composed of a resection tip (2): a resection part (3) that is swollen or inflated in such tube-like organs (7) and is displaced or moved back and forth therein to provide tumor resection; a hardening surface (4) provided on the outer surface of said resection part (3) to shave and destroy such tumoral tissues; a catheter section (5) providing access to an endoluminal site; and an injection terminal (6) capable to inflate said resection part (3) by injecting air or fluid.




Figure-2

4 4 4 4 4 4 4 4

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139498	Bayer Aktiengesellschaft., Germany	770/1999
139499	F. Hoffmann-La Roche AG., Switzerland	617/2000
139500	Merck Patent HmbH., Germany	671/2000
139501	Insung Powdertech Co. Limited., Korea	1081/2004
139502	Novibra GmbH., Germany	412/2005
139503	F. Hoffmann-La Roche AG., Switzerland	760/2007

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488